Movement Alert｜Novartis Rises 3.11% in Pre-Market Trading, Multiple Pipeline Catalysts Drive Positive Sentiment

Market Focus06-11

On June 11, Novartis rose 3.11% in pre-market trading, trading at $152.71/share, with trading volume of $1.1354 million. The stock gained on a cluster of positive pipeline developments.

On the news front, Novartis announced that its experimental muscular dystrophy therapy del-brax achieved the primary endpoint and key secondary endpoints in a Phase I/II study. On the same day, the company entered a molecular glue drug collaboration with Orionis Biosciences valued at over $1.4 billion in total. Additionally, the combination of Tafinlar and Mekinist received approval from China's National Medical Products Administration for a new indication in BRAF V600E mutation-positive differentiated thyroid cancer. The convergence of multiple pipeline milestones has bolstered market expectations for the company's R&D portfolio value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168811199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168811199","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Novartis Rises 3.11% in Pre-Market Trading, Multiple Pipeline Catalysts Drive Positive Sentiment","media":"Market Focus","content":"<p><p>On June 11, Novartis rose 3.11% in pre-market trading, trading at $152.71/share, with trading volume of $1.1354 million. The stock gained on a cluster of positive pipeline developments.</p><p>On the news front, Novartis announced that its experimental muscular dystrophy therapy del-brax achieved the primary endpoint and key secondary endpoints in a Phase I/II study. On the same day, the company entered a molecular glue drug collaboration with Orionis Biosciences valued at over $1.4 billion in total. Additionally, the combination of Tafinlar and Mekinist received approval from China's National Medical Products Administration for a new indication in BRAF V600E mutation-positive differentiated thyroid cancer. The convergence of multiple pipeline milestones has bolstered market expectations for the company's R&D portfolio value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novartis Rises 3.11% in Pre-Market Trading, Multiple Pipeline Catalysts Drive Positive Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novartis Rises 3.11% in Pre-Market Trading, Multiple Pipeline Catalysts Drive Positive Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-11 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 11, Novartis rose 3.11% in pre-market trading, trading at $152.71/share, with trading volume of $1.1354 million. The stock gained on a cluster of positive pipeline developments.</p><p>On the news front, Novartis announced that its experimental muscular dystrophy therapy del-brax achieved the primary endpoint and key secondary endpoints in a Phase I/II study. On the same day, the company entered a molecular glue drug collaboration with Orionis Biosciences valued at over $1.4 billion in total. Additionally, the combination of Tafinlar and Mekinist received approval from China's National Medical Products Administration for a new indication in BRAF V600E mutation-positive differentiated thyroid cancer. The convergence of multiple pipeline milestones has bolstered market expectations for the company's R&D portfolio value.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"","article_id":"1168811199","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168811199","pubTimestamp":1781178493,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 11, Novartis rose 3.11% in pre-market trading, trading at $152.71/share, with trading volume of $1.1354 million. The stock gained on a cluster of positive pipeline developments.On the news...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华"},"translate_title":"动向提示|诺华盘前涨3.11%多个管线催化剂带动积极情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1},"content_text":"On June 11, Novartis rose 3.11% in pre-market trading, trading at $152.71/share, with trading volume of $1.1354 million. The stock gained on a cluster of positive pipeline developments.On the news front, Novartis announced that its experimental muscular dystrophy therapy del-brax achieved the primary endpoint and key secondary endpoints in a Phase I/II study. On the same day, the company entered a molecular glue drug collaboration with Orionis Biosciences valued at over $1.4 billion in total. Additionally, the combination of Tafinlar and Mekinist received approval from China's National Medical Products Administration for a new indication in BRAF V600E mutation-positive differentiated thyroid cancer. The convergence of multiple pipeline milestones has bolstered market expectations for the company's R&D portfolio value.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168811199","isCrawlerRequest":true}